ERBB2 and adenocarcinoma: However, although about half of the cases with HER2/neu expression scores 1, 2 and 3 were observed in patients with adenocarcinoma, which is inconsistent with the results of the study by Mazieres et al.12In addition to the assessment method used for HER2/neu overexpression, another source of difference among studies is the cut‐off used for reporting HER2/neu expression as positive.